Meissa Vaccines, Inc. news

? Meissa’s intranasal recombinant live attenuated COVID-19 vaccine, MV-014-212, induced mucosal as well as systemic antibodies against SARS-CoV-2 and two variants of concern

? MV-014-212 was built on the company’s AttenuBlock platform and is designed to be appropriately attenuated, genetically stable, and optimized to drive robust, broad, and durable immunity

· No vaccine is currently approved to protect against respiratory syncytial virus (RSV)

· RSV is the leading cause of infant hospitalization in the United States and is considered the “missing” pediatric vaccine

· Previous clinical data in seropositive adult and pediatric participants showed MV-012-968 was well-tolerated, appropriately attenuated, and stimulated RSV-specific mucosal IgA, des

Initial preclinical data shows MV-014-212 induced a SARS-CoV-2-specific mucosal IgA response, generated serum neutralizing antibodies, and provided efficacy against challenge

REDWOOD CITY, Calif., March 16, 2021 – Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today that the company has received clearance from

- The randomized, double-blind, placebo-controlled challenge study is designed to evaluate safety and prophylactic efficacy of MV-012-968 against symptomatic respiratory syncytial virus (RSV)

- Previous clinical data shows MV-012-968 is well-tolerated, heavily attenuated, and induces an RSV-specific mucosal IgA response in healthy seropositive adults and pediatric participants

Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands

Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific mucosal IgA response in the majority of healthy adult, serop